2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago · CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago · 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025. Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 ...
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In …
WEB5 days ago · 2seventy bio will focus exclusively on the commercialization and continued development of Abecma. Price Action: TSVT stock is down 7.65% at $4.41, and BMY stock is down 2.90% at $49.47 at last ...
Struggling 2Seventy scraps a key cancer study | BioPharma Dive
WEB5 days ago · The decision announced Wednesday was made, in part, to help ensure 2Seventy breaks even financially next year. The biotechnology company expects ending the trial will save $80 million in the near term. 2Seventy recorded a $27 million loss from operations in the second quarter and, as of June 30, …
Citing enrollment challenges, Bristol Myers and 2seventy scrap …
WEB5 days ago · Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial. The trial had been evaluating Abecma as a first-line maintenance treatment in patients with newly ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago · About 2seventy bio. Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. ... BioSpace is the digital hub for life science news and jobs. We provide essential ...
2seventy bio Announces New Strategic Path Forward
WEBJan 30, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 30, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.
2seventy bio Announces Completion of Oncology and …
WEBApr 1, 2024 · Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS).
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBJan 30, 2024 · An estimated 150 employees from 2seventy bio will transition to Regeneron to continue their work on cell therapy programs and will remain located in Cambridge, MA and Seattle, WA.
2seventy bio Completes Spin Transaction and Launches …
WEBNov 4, 2021 · 2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company.
- Some results have been removed